UK Sets 11 as Minimum Age for Puberty Blocker Trial
- Minimum age of 11 set for UK puberty blocker trial
- Trial aims to assess risks and benefits of puberty blockers on gender-questioning children
- Parental consent and understanding of risks required for participation
- Regulator initially suggested minimum age of 14 due to safety concerns
- Trial led by King's College London, with estimated 226 young participants
The UK puberty blocker trial has set a minimum age of 11 for participation, with 12 for males, despite initial concerns from regulators for a higher age limit due to potential long-term risks. The trial, led by King's College London, aims to assess the impact of puberty blockers on gender-questioning children. Officials said parental consent and understanding of risks are required for participation.
The planned Pathways Trial was paused in February 2026 after the Medicines and Healthcare products Regulatory Agency (MHRA) raised safety concerns and suggested introducing a minimum age of 14, where none had been set previously.
The trial is a response to the UK's indefinite ban on puberty blockers for under-18s, which was introduced in May last year. Sources confirmed that the ban was made indefinite across the UK in December last year.
Regulator Concerns and Trial Pause
The MHRA raised safety concerns about the trial, suggesting a minimum age of 14 due to potential long-term risks. However, discussions with the research team have allowed 'a number of safeguards', including parental consent and understanding of risks.
Government sources said the regulator's concerns were taken into account, and the trial was paused to address these concerns. The trial was initially expected to recruit an estimated 226 young people over the next three years, with the youngest participants expected to be 10 to 11 for biological females and 11 to 12 for biological males.
Witnesses said the rigorous selection process meant participants would be carefully chosen to ensure their safety and well-being.
Expert Views on Puberty Blocker Trial
Experts behind the puberty blockers study responded to concerns, stating that the trial could be the safest option for patients. They said the trial would provide valuable insights into the risks and benefits of puberty blockers for gender-questioning children.
Officials said the trial would help young people and clinicians make better-informed decisions in the future. Sources confirmed that the trial would be overseen by the National Institute for Health and Care Research (NIHR).
Researchers said the trial would build an evidence base to help young people and clinicians make informed decisions. They also said the trial would provide a safe and controlled environment for participants to receive puberty blockers.
Historical Context of Puberty Blocker Trial
The UK government introduced emergency legislation to temporarily ban private and overseas prescriptions of puberty blockers for new patients under 18 in May last year. The temporary ban was made indefinite across the UK in December last year.
The Medicines and Healthcare products Regulatory Agency (MHRA) had pointed to insufficient evidence on the safety and effectiveness of puberty blockers based on a review by NICE and interim advice from the Cass review.
Government sources said the regulator's concerns were taken into account, and the trial was designed to address these concerns. The trial is expected to provide valuable insights into the risks and benefits of puberty blockers for gender-questioning children.
Human Impact of Puberty Blocker Trial
The trial is expected to have a significant impact on the lives of gender-questioning children and their families. Officials said the trial would provide a safe and controlled environment for participants to receive puberty blockers.
Sources confirmed that the trial would help young people and clinicians make better-informed decisions in the future. Researchers said the trial would build an evidence base to help young people and clinicians make informed decisions.
Witnesses said the trial would provide a valuable opportunity for participants to receive puberty blockers in a safe and controlled environment. They also said the trial would help to address the concerns of regulators and provide a better understanding of the risks and benefits of puberty blockers.